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Introduction {#sec1}
============

Hematopoiesis gives rise to a spectrum of cell types that are essential for normal immune and homeostatic functions throughout the body. Within this differentiation cascade, cells of the myeloid lineage give rise to bone-resorbing osteoclasts (OCs). In bones, OC differentiation from myeloid precursors (MPs) and subsequent OC function are regulated by microenvironmental cues from the surrounding stromal cells, in particular bone-forming osteoblasts. Downstream signaling through the CSF1/CSF1R and RANKL/RANK axes in the MPs, and later in the OCs, results in the activation of multiple signaling pathways and transcription factors (TFs) essential for OC differentiation, including PU.1, MITF, and NFATc1 ([@bib7], [@bib21], [@bib22]).

The ETS family member PU.1 is essential for myeloid lineage commitment ([@bib10]). We have shown that PU.1 and MITF physically and genetically interact to regulate a complex TF network regulating the course of OC differentiation, and ultimately OC function ([@bib2], [@bib12], [@bib19]). Several of these PU.1-bound TF gene loci are present at the distal enhancer and "superenhancer" elements known to contain other TF-binding loci ([@bib2]).

Eomesodermin (EOMES) was first identified as an essential developmental molecule controlling extraembryonic trophoblast formation ([@bib4], [@bib16]). EOMES has since been shown to be essential for (1) regulating mesoderm cell function and digit formation and (2) cerebral cortex development, patterning, and neurogenesis ([@bib16], [@bib18], [@bib20]). However, in postnatal life, EOMES has been predominately described along with the closely related T-box TF, T-bet, as a key regulator of CD8^+^ T cell and natural killer (NK) cell maturation and function ([@bib6], [@bib9], [@bib14]).

In this study, we have demonstrated by motif-finding algorithms that the T-box TF EOMES is highly enriched in PU.1 and MITF co-bound peaks in MPs and OCs. Furthermore, EOMES physically interacts with PU.1 and MITF, co-binding these factors in a PU.1/MITF/EOMES complex at key OC-specific TF genomic loci, which we have previously shown to be bound by PU.1 and MITF ([@bib2]). EOMES knockdown in murine MPs leads to decreased OC differentiation and function *in vitro* and *in vivo*. Although EOMES is associated with other hematopoietic lineages, this is the first study demonstrating the requirement of EOMES in OC differentiation, where it is a novel co-partner of PU.1 and MITF.

Results {#sec2}
=======

EOMES Interacts with PU.1 and MITF to Regulate OC-Determining Gene Loci {#sec2.1}
-----------------------------------------------------------------------

We previously performed PU.1 and MITF chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-seq) in MPs and OCs. This revealed a conserved TF network regulating OC differentiation that is governed by PU.1 and MITF ([@bib2]). To identify any novel binding partners that may also be important in establishing the OC TF network, we performed motif analysis of PU.1/MITF co-bound peaks in OCs. Apart from PU.1/ETS and MITF/E-Box motifs, a T-Box signature typical for EOMES/TBR2 was most enriched in PU.1/MITF co-bound peaks ([Figure 1](#fig1){ref-type="fig"}A). To evaluate the validity of these findings, we first analyzed a publicly available dataset of EOMES ChIP-seq from murine embryonic cerebral cortex (MECC) ([@bib17]). We evaluated the tag densities of both PU.1 and MITF in both MPs and OCs around EOMES-bound regions in MECC. These results indicated that the EOMES-occupied loci were associated with regions with higher PU.1 and MITF binding, as determined by K means clustering ([Figure 1](#fig1){ref-type="fig"}B). Furthermore, of the 17,089 genes associated with PU.1 binding in OCs, 31% of the genes were also associated with EOMES binding in MECC ([Figure 1](#fig1){ref-type="fig"}C). Tag densities of PU.1 occupancy from both MPs and OCs around MECC EOMES ChIP-seq peaks indicated that within 500 bp of EOMES peaks several PU.1 peaks may exist ([Figure S1](#mmc1){ref-type="supplementary-material"}A). To examine whether PU.1 could physically interact with EOMES, we overexpressed V5-tagged EOMES with HA-tagged PU.1 in HEK293 cells followed by co-immunoprecipitation (coIP). Upon HA-PU.1 pull-down and probing for V5-EOMES by V5 antibody, an EOMES/PU.1 interaction was present ([Figure 1](#fig1){ref-type="fig"}D; left). In complementary experiments when EOMES complexes were pulled down with V5 antibody, a PU.1/EOMES interaction was also detected ([Figure 1](#fig1){ref-type="fig"}D; right). Next, we scrutinized whether MITF-occupied loci in OCs were also associated with EOMES-bound loci in MECC and found that 12% of the MITF-occupied sites overlapped with the EOMES-bound genes ([Figure 1](#fig1){ref-type="fig"}E), with the highest MITF tag density in MPs and OCs within 50 bases of EOMES peak centers in MECC ([Figure S1](#mmc1){ref-type="supplementary-material"}B). FLAG-tagged MITF and V5-tagged EOMES overexpression in HEK293 cells followed by coIP also revealed an interaction between MITF and EOMES ([Figure 1](#fig1){ref-type="fig"}F).Figure 1EOMES Interacts with PU.1 and MITF to Regulate OC-Determining Gene Loci(A) Motifs enriched in MITF and PU.1 overlapped peaks in OCs with their percentage of occurrence.(B) K means clustering diagram showing the density of PU.1 and MITF ChIP-seq fragments in MPs and OCs around EOMES-bound regions in murine embryonic cerebral cortex.(C) Overlap of bound gene loci between EOMES ChIP-seq from MECC and PU.1 ChIP-seq in OCs.(D) coIP experiments involving HA-PU.1 IP followed by V5-EOMES western blot in HEK293 cells overexpressing V5-tagged EOMES and HA-tagged PU.1 (left). Complementary experiments involving V5-EOMES immunoprecipitation (IP) followed by HA-PU.1 western blot in the same cells (right).(E) Overlap of gene loci between EOMES ChIP-seq from MECC and MITF ChIP-seq in OCs.(F) coIP experiments involving FLAG-MITF IP followed by V5-EOMES western blot in HEK293 cells overexpressing V5-tagged EOMES and FLAG-tagged MITF (left). Complementary experiments involving V5-EOMES IP followed by FLAG-MITF western blot in the same cells (right).See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Myeloid-Specific Knockdown of EOMES Disrupts the Expression of OC-Specific TFs {#sec2.2}
------------------------------------------------------------------------------

We have shown that the PU.1-MITF regulatory axis is a predominant regulator of the OC-specific TF network ([@bib2]). To evaluate the molecular functions regulated by EOMES, we examined the molecular processes enriched in EOMES-associated genes from MECC using the ToppGene suite ([@bib3]) and found that TF and promoter binding were highly enriched ([Figure S2](#mmc1){ref-type="supplementary-material"}A). To verify if EOMES is essential for the expression of any of the TFs identified in the PU.1-MITF regulatory network, we used a tamoxifen-inducible, myeloid lineage-specific *Csf1rTAMCre* in combination with *Eomes*^*fl/fl*^ mice to generate *Eomes*^*ΔMP/ΔMP*^ mice with tamoxifen induction. EOMES knockdown in MPs was confirmed by both genotyping and western blot ([Figure 2](#fig2){ref-type="fig"}A). *Eomes*^*ΔMP/ΔMP*^ mice showed a significant decrease in EOMES protein expression in MPs compared with controls (p = 0.029, [Figure 2](#fig2){ref-type="fig"}A). *In vitro* differentiation of MPs into OCs from *Eomes*^*ΔMP/ΔMP*^ mice and control littermates revealed a significant reduction in the upregulation of pro-osteoclastogenic TFs, *Nfatc1*, *Fosl2*, *Prdm1*, and *Jun-B* when compared with controls (p \< 0.05, [Figure 2](#fig2){ref-type="fig"}B). Although *cFos* upregulation in *Eomes*^*ΔMP/ΔMP*^ OCs was reduced compared with controls, this did not reach statistical significance (p = 0.383, [Figure 2](#fig2){ref-type="fig"}B). In addition, TFs with known anti-osteoclastogenic effects, *Irf8* and *Bcl6*, trended to be significantly increased in OCs following EOMES deletion (p = 0.074 and 0.060, respectively, [Figure S2](#mmc1){ref-type="supplementary-material"}B).Figure 2Myeloid-Specific Knockdown of *Eomes* Disrupts the Expression of OC-Specific TFs(A) Knockdown of EOMES specifically in MPs (*Eomes*^*ΔMP/ΔMP*^) was confirmed by (1) DNA genotyping PCR (with historical genomic tail-tip extracted DNA as reference) and (2) western blot analysis (with quantification, n = 2) following 3 days treatment with tamoxifen using myeloid-lineage-specific *Csf1rTAMCre* in combination with *Eomes*^*fl/fl*^ mice when compared with *Eomes*^*fl/fl*^, *Eomes*^*fl/+*^, or *Eomes*^*+/+*^ controls.(B) Evaluation of key pro-osteoclastogenic TFs by quantitative real-time RT-PCR (n = 2--6). For all figures and subfigures, data are represented as mean ± SD for all bar graphs and all images are representative. \*p \< 0.05, \*\*p \< 0.01. KO, knockout; WT, wild-type.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

The PU.1-MITF-EOMES Complex Drives Nfatc1 Expression by Association with the Looping Peak within the Nfatc1 Superenhancer {#sec2.3}
-------------------------------------------------------------------------------------------------------------------------

We have recently identified a conserved intronic enhancer in the OC master regulator *Nfatc1* that requires PU.1 to loop back to the proximal promoter by means of changes in chromatin conformation ([@bib2]). Thus we evaluated whether EOMES directly binds to this *Nfatc1* enhancer co-bound by PU.1 and MITF ([Figure 3](#fig3){ref-type="fig"}A). There was significant enrichment of PU.1, MITF, and EOMES at the *Nfatc1* enhancer in both MPs and OCs when compared with IgG controls (p \< 0.05). Interestingly, whereas PU.1 and MITF occupancy is sustained at *Nfatc1* as MPs differentiated into OCs ([Figure 3](#fig3){ref-type="fig"}A), EOMES is present at a lower abundance in OCs when compared with MPs (p = 0.068, [Figure 3](#fig3){ref-type="fig"}A).Figure 3The PU.1-MITF-EOMES Complex Drives *Nfatc1* Expression by Association with the Looping Peak within the *Nfatc1* Superenhancer(A) Conventional ChIP of PU.1, MITF, and EOMES binding at the conserved intronic enhancer of *Nfatc1* in MPs and OCs (n = 2--3).(B) HA-PU.1, FLAG-MITF, or V5-EOMES immunoprecipitation (IP) followed by HA-PU.1, FLAG-MITF, or V5-EOMES western blot in HEK293 cells co-transfected with FLAG-MITF, HA-PU.1, and V5-EOMES.(C) Sequential ChIP using PU.1, MITF, and EOMES antibodies following initial PU.1 ChIP in MPs (ReChIP) at the looping peak of *Nfatc1*. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.

Next, we verified whether EOMES could represent a subunit of the PU.1-MITF complex by co-expression of FLAG-MITF, HA-PU.1, and V5-EOMES in HEK293 cells. In a series of complimentary experiments, when the total cell lysate was pulled down with (1) FLAG-MITF and probed for V5-EOMES and HA-PU.1 (left), (2) HA-PU.1 and probed for V5-EOMES and FLAG-MITF (middle), or (3) V5-EOMES and probed for FLAG-MITF and HA-PU.1 (right), all signals were detected in the immunoprecipitations ([Figure 3](#fig3){ref-type="fig"}B). These results indicated that PU.1, MITF, and EOMES all interact and can remain in a complex together. Previously, we have shown by ReChIP analysis that PU.1 and MITF can simultaneously occupy specific regions of chromatin ([@bib8]). We again employed ReChIP to determine if EOMES can also interact with PU.1 and MITF while all occupy a regulatory site near the *Nfatc1* gene. For ReChIP, soluble chromatin from MPs was pulled down using the PU.1 antibody. After dissociation of the chromatin complex from the antibody, sequential ChIP was performed using PU.1, MITF, and EOMES antibodies. Using qRT-PCR with primers designed at the looping peak of *Nfatc1*, we observed that ∼34% of the first immunoprecipitate (input for the second ChIP) was pulled down with the PU.1 antibody ([Figure 3](#fig3){ref-type="fig"}C). MITF was able to pull down ∼23% of the first immunoprecipitate, and EOMES was able to pull down ∼12%, all significantly more than the IgG control (∼2.7%) (p \< 0.01, [Figure 3](#fig3){ref-type="fig"}C). This result further indicates that PU.1, MITF, and EOMES can all interact in MPs and do so to regulate the expression of OC TF network genes like *Nfatc1*.

Myeloid-Specific EOMES Deletion Decreased OC Differentiation and Function *In Vivo* and *In Vitro* {#sec2.4}
--------------------------------------------------------------------------------------------------

*Eomes*^*ΔMP/ΔMP*^ mice possessed increased bone mass when compared with control *Eomes*^*fl/fl*^ mice upon micro-computed tomographic analysis ([Figure 4](#fig4){ref-type="fig"}A). Most notably, there was a significant increase in bone volume/total volume in the distal femoral metaphysis (p = 0.013) and cortical thickness in both the distal femoral metaphysis (p = 0.038) and diaphysis (p = 0.016) ([Figure 4](#fig4){ref-type="fig"}B). In addition, *Eomes*^*ΔMP/ΔMP*^ mice displayed a significant increase in cumulative bone mineral density (BMD) (p = 0.009) and trabecular volume/all bone volume (p = 0.016), a trend toward a significant increase in trabecular number (p = 0.065), and a decrease in trabecular spacing (p = 0.050, [Figure 4](#fig4){ref-type="fig"}B). The statistical trend and decrease in trabecular pattern factor (p = 0.082) in *Eomes*^*ΔMP/ΔMP*^ mice indicates greater trabecular connectivity ([Figure 4](#fig4){ref-type="fig"}B). Based on our MP-specific deletion of EOMES, these results suggest that decreased osteoclastic bone resorption is responsible for the bone phenotype observed in *Eomes*^*ΔMP/ΔMP*^ mice. In further support of this hypothesis, histomorphometric analysis revealed a significant reduction in both OC number (p = 0.038) and OC surface (p = 0.016) per bone surface in *Eomes*^*ΔMP/ΔMP*^ mice compared with controls ([Figures 4](#fig4){ref-type="fig"}C and 4D). *In vitro* differentiation of OCs derived from *Eomes*^*ΔMP/ΔMP*^ mice showed a significant reduction in the formation of TRAP-positive multinucleated OCs (p = 0.038, [Figures 4](#fig4){ref-type="fig"}E and 4A) and significant decrease in the expression of the OC marker genes *Acp5, Ctsk, Calcr,* and *Oscar* (p \< 0.05, [Figure 4](#fig4){ref-type="fig"}F).Figure 4Myeloid-Specific *Eomes* Deletion Decreased OC Differentiation and Function *In Vivo* and *In Vitro*(A) Femoral micro-computed tomographic (μCT) cross-sectional images in the craniocaudal view and the distal femoral metaphysis in the proximodistal view from 8-day-old *Eomes*^*ΔMP/ΔMP*^ mice and *Eomes*^*fl/fl*^ controls. Scale bars, 1 mm.(B) μCT quantification of bone morphometric variables (n = 3). BMD, bone mineral density; BV/TV, bone volume/total volume; Ct.Th, cortical thickness; Tb.V/AV, trabecular volume/all bone volume; Tb.N, trabecular number; Tb.Sp, trabecular spacing; Tb.Pf, trabecular pattern factor; Tb.Th, trabecular thickness.(C) Tartrate-resistant acid phosphatase (TRAP) staining (in violet) with hematoxylin counterstain to identify OCs in the distal femoral metaphysis of mice in (A). Scale bars, 50 μm.(D) Histomorphometric quantification of Oc.S/BS and Oc.N/BS from (C) (n = 3). Oc.N/BS, OC number per bone surface; Oc.S/BS, OC surface per bone surface.(E and F) (E) Representative images of *in vitro* TRAP-positive multinucleated OC formation from *Csf1rTAMCre;Eomes*^*fl/fl*^ and *Eomes*^*fl/fl*^ mice and quantification per high-powered field (HPF) (n = 2). (F) RT-PCR analysis of genes regulating OC differentiation and function in *Eomes*^*fl/fl*^ (WT) MPs and OCs and *Eomes*^*ΔMP/ΔMP*^ (*Eomes KO*) OCs after differentiation (n = 2--6). \*p \< 0.05, \*\*p \< 0.01. KO, knockout; WT, wild-type.

Discussion {#sec3}
==========

EOMES is the earliest expressed T-box gene during development ([@bib4]). Constitutive or conditional EOMES deletion has demonstrated its crucial role in lineage commitment, differentiation, and maintenance of multiple stem and progenitor cell populations ([@bib15]). The functionality of EOMES in post-natal life is best described in the context of the immune system, where it is a key regulator of cell-mediated immunity and T cell function ([@bib9], [@bib14]). Here, the essential role of EOMES is evident in that it is a disease susceptibility loci for multiple diseases linked with T cell dysfunction ([@bib1], [@bib11]).

One of the key insights obtained in our study is the discovery that EOMES is a functional partner of PU.1 and MITF in regulating the TF network governing OC differentiation. Although EOMES is capable of inducing the full array of mesodermal cell types and genes ([@bib20]), expression and functionality of EOMES in bone-resorbing OCs, or any cell of the myeloid lineage for that matter, has not been reported. Our results confirm that like the master myeloid regulator PU.1 ([@bib2]), EOMES modulates OC differentiation by promoting the expression of pro-osteoclastogenic TFs and inhibiting the expression of TFs that negatively regulate OC differentiation, albeit to a lesser magnitude than PU.1. Our *in silico* analysis indicated high enrichment of the EOMES-binding motif in PU.1-MITF co-bound loci. Furthermore, when PU.1 and MITF tag densities were mapped against EOMES ChIP-seq peaks from MECC ([@bib17]), both PU.1 and MITF tags were enriched within 50 bp of the EOMES peak centers.

Our *in silico* results led us to query whether EOMES could interact with PU.1, MITF, or both. No physical interaction between EOMES and either MITF or ETS family TFs, like PU.1, has been previously reported. However, previous work has shown that EOMES regulates the expression of genes regulated by (1) MITF, such as granzyme B and interferon-γ, and (2) ETS1 and MEF (ETS family members), including perforin in certain lymphoid cell populations ([@bib5]). Interestingly, in CD8^+^ T cells, different chromatin conformations are associated with ETS family member and EOMES binding ([@bib13]). In the naive cell state, there is increased accessibility by ETS members, and in the memory cell state, an open conformation allows more ready access by EOMES ([@bib13]). In our study, we were able to demonstrate in the myeloid compartment that the ETS family TF, PU.1, and MITF, are in a complex with EOMES, which is found at the looping peak of the *Nfatc1* enhancer. These results indicate that in the looping peak of *Nfatc1*, EOMES associates with the PU.1-MITF complex in at least a subset of MPs. Considering that only a subset of MPs differentiate to form OCs *in vivo*, EOMES might be more specifically present only in those MPs committing to the OC precursor population. Previous work has shown that EOMES changes its binding profile during transition from one cell type to another, suggesting that its function may change at different points of differentiation ([@bib23]). Conventional ChIP revealed that like PU.1 and MITF, EOMES is recruited and bound to a key TF locus essential for OC differentiation. Interestingly, we detected a statistical trend toward a lower abundance of EOMES binding on *Nfatc1* in OCs when compared with MPs. This suggests that EOMES is more essential in establishing chromatin dynamics in MPs than in differentiating OCs.

We demonstrated that MP-specific EOMES deletion disrupted the PU.1-MITF TF network and resulted in osteopetrosis *in vivo*, a finding consistent with decreased OC differentiation and function. Historically, EOMES knockout mice arrest at the blastocyst stage, resulting in early embryonic lethality ([@bib16]). Lineage-specific EOMES deletion within the hematopoietic hierarchy using *Vav-Cre* has been reported ([@bib6]). However, whereas there was a global reduction in NK cells, which are of lymphoid origin, no investigation on changes within the myeloid lineage were reported ([@bib6]).

In summary, the work presented here is the first evidence of EOMES having a functional role in any cell of the myeloid lineage, where EOMES is a novel binding partner of PU.1 and MITF and works in conjunction with these factors to regulate the OC TF network.

Limitations of the Study {#sec3.1}
------------------------

Although the systems biology approaches we used to identify EOMES as a partner of PU.1 and MITF are robust, they also give rise to several other "hits" due to the vast number of ETS DNA-binding domains. We filtered most of the ETS motifs as a subset of binding regions associated with PU.1, which is an ETS factor. An additional limitation is that due to the lack of reagents, the temporal kinetics of PU.1, MITF, and EOMES recruitment to target loci was not established in the current study.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Software Availability {#appsec3}
==============================

Raw images of immunoprecipitation and western blot data used in this has been deposited to Mendeley depository and can be accessed at URL:<http://dx.doi.org/10.17632/wdv72kxgjg.1>.
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Document S1. Transparent Methods and Figures S1 and S2
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